1Lam MSH, Ignoffo RJ. A guide to clinically relevant drug interactions in ontology[J]. J Oncol Pharm Pratt, 2003, 9(2): 45-85.
2Verschraagen M, Kedde MA, Hausheer FH, et al. The chemical reactivity of BNP7787 and its metabolitc mesna with the cytostatic agent cisplatin: comparsion with the nucleophiled thiosulfate, DDTC, glutathione and its disulfide GSSG[J]. Cancer Chemother Pharmacol, 2003,51(6): 499-504.
3Gabison A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies[J]. Clin Pharmacokinet, 2003, 42(5): 419-436.
4Vaishampayan U, Parchment RE, Jasti BR, et al. Taxanes: an overview of the pharmacokinetics and pharmacodynamics[J]. Urology, 1999, 54 (Suppl 6A): 22-29.
5Danesi R, Innocenti F, Fogli S, et al. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients [J]. Br J Clin Pharmacol,2002, 53(5): 508-518.
6Kruijtzer CMF, Beijnen JH, Schellens JHM, Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal traet and liver: an overview [J]. Oncologist, 2002, 7(6): 516-530.
7Beijnen JH, Schellens JH. Drug interactions in oncology[J]. Lancet Ontology, 2004, 5: 489-496.
8Bardelmeijer HA, Ouwehand M, Buckle T, et al, Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir [J].Cancer Res, 2002, 62(21): 6158-6164.
9Kruijtzer CMF, Beijnen JH, Rosing H, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918[J]. J Clin Oncol, 2002, 20(13): 2943-2950.
10Huitema ADR, Kerbusch T, Tibben MM, et al. Reduction of cyclophosphamide-bioactivation of thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens[Jl. Cancer Chemother Pharmacol, 2000, 46 (2):119-127.
